Vertex hepatitis

Vertex hepatitis

Vertex Pharmaceuticals showed an impressive ability to knock out the virus in patients for the serious liver disease. In a study its Prove of the previous treatment who have failde with pegylated interferon and ribavirin, 52% of those who received telaprevir saw the virus fall to undetectable levels and remain there 12 weeks after stopping treatment. The percentage with undetectable virus 24 weeks after stopping treatment will yield the critical measure known as (SVR)sustained viral response.

Jason Kolbert, an analyst with Susquehanna Financial Group said: "Efficacy in non-responders is huge. No one should have any doubt about whether this drug works" .

Hepatitis C is a blood borne liver disease that can lead to chronic liver disease, liver cancer, cirrhosis and death. The virus affects an estimated 3.2 million people in the United States alone
and some 170 million worldwide.

In that study, 69% of patients in the telaprevir combination group had the virus fall to undetectable levels following 24 weeks of treatment, compared with a 46% SVR rate after 48 weeks of standard treatment.

Now if looking for the side effects then you seen skin rash and anemia. Several companies are developing potential rival medicines but telaprevir is widely expected to be the first in the market and potential demand of it is increasing.